Identification of Liver Fibrosis Biomarkers

NCT06819917

Status	RECRUITING
Sponsor	Roche Diagnostics GmbH
Enrollment	575 participants

Key Eligibility Criteria

Inclusion (6)

- Patients scheduled for biopsy (or F0-F2 patients that underwent biopsy within the last 6 months but at least 1 month ago) suspected of having hepatic fibrosis due to NAFLD (NAFL/NASH) or patients with MASLD or MASH
- Any FIB-4 value available
- Any Fibroscan value available
- Written and signed informed consent present
- Patients aged e 18 years to d 75 years at the time of the blood draw

... and 1 more (see full listing online)

Exclusion (10)

- Vulnerable person: person deprived of liberty by a judicial or administrative decision and/or person under psychiatric care
- Self-reported pregnancy or lactating females
- Disease related to other etiologies, including alcoholic liver disease (alcoholic steatohepatitis), MetALD, specific etiology SLD (e.g. DILI or monogenic disease), cryptogenic SLD, viral hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, human immunodeficiency virus, Wilson's disease, Hemochromatosis, alpha-1 antitrypsin deficiency
- Any type of carcinoma, unless it is at least 5 years in remission
- Prior liver transplant

... and 5 more (see full listing online)

Locations (2 total)

Hvidovre Hospital, Copenhagen, Denmark
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany